Peculiarities of the course of multisystem inflammatory syndrome associated with COVID-19 in children: from literature review to own clinical observations
Keywords:children, SARS-CoV-2, COVID-19, MIS-C, Kawasaki disease, hyperinflammatory syndrome
Current data suggest that during the global pandemic of COVID-19 children are less affected than adults and most of them are asymptomatic or with mild symptoms. However, recently, cases of pediatric patients who have developed severe inflammatory syndrome temporally related to SARS-CoV-2 have been reported both in the USA and Europe. These reports, although sharing features with other pediatric syndromes such as Kawasaki disease (KD), Kawasaki disease shock syndrome, macrophage activated syndrome, and toxic shock syndrome, seem to outline a novel entity syndrome, characterized by cytokine storm with elevated inflammatory markers and typical clinical finding. Clinical characteristics are greater median age than KD, higher frequency of cardiac involvement and gastrointestinal symptoms, lower frequency of coronary anomalies. We report a summary of the current evidence about clinical features, pathogenesis, therapy strategies, and outcome of this novel syndrome.
Dong Y., Mo X., Hu Y. et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020. 145(6). e20200702. doi: 10.1542/peds.2020-0702 [PubMed] [Google Scholar].
Li W., Moore M.J., Vasilieva N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003. 426(6965). 450-454 [PMC free article] [PubMed] [Google Scholar].
Castagnoli R., Votto M., Licari A. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020 April. doi: 10.1001/jamapediatrics.2020.1467. Online ahead of print [PubMed] [Google Scholar].
Koné-Paut I., Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020. 6. e001333 [PMC free article] [PubMed] [Google Scholar].
Verdoni L., Mazza A., Gervasoni A. et al. An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020. 395(10239). 1771-1778 [PMC free article] [PubMed] [Google Scholar].
Jones V.G., Mills M., Suarez D. et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp. Pediatr. 2020. 10. 537-540 [PubMed] [Google Scholar].
Riphagen S., Gomez X., Gonzalez-Martinez C., Wilkinson N., Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020. 23. 395(10237). 1607-1608 [PMC free article] [PubMed] [Google Scholar].
Belhadjer Z., Méot M., Bajolle F. et al. Acute heart failure in multisystem inflammatory syndrome children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020 doi.org/10.1161/CIRCULATIONAHA.120.048360 Online ahead of print [PubMed] [Google Scholar].
Licciardi F., Pruccoli G., Denina M. et al. SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children. Pediatrics. 2020. May 21. e20201711. doi: 10.1542/peds.2020-1711 [PubMed] [Google Scholar].
Toubiana J., Poirault C., Corsia A., Bajolle F., Fourgeaud J., Angoulvant F. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020 Jun. 369. doi: 10.1136/bmj.m2094 [PMC free article] [PubMed] [Google Scholar].
Makino N., Nakamura Y., Yashiro M. et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. J. Epidemiol. 2015. 25. 239-245 [PMC free article] [PubMed] [Google Scholar].
Esper F., Shapiro E.D., Weibel C., Ferguson D., Landry M.L., Kahn J.S. Association between a novel human coronavirus and Kawasaki disease. J. Infect. Dis. 2005. 191. 499-502 [PMC free article] [PubMed] [Google Scholar].
Ebihara T., Endo R., Ma X., Ishiguro N., Kikuta H. Lack of association between New Haven coronavirus and Kawasaki disease. J. Infect. Dis. 2005. 192. 351-352 [PMC free article] [PubMed] [Google Scholar].
Shirato K., Imada Y., Kawase M., Nakagaki K., Matsuyama S., Taguchi F. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J. Med. Virol. 2014. 86. 2146-2153 [PMC free article] [PubMed] [Google Scholar].
Ravelli A., Minoia F., Davì S. et al. Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann. Rheum. Dis. 2016. 75. 481-489 [PubMed] [Google Scholar].
Kanegaye J.T., Wilder M.S., Molkara D. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009. 123. e783-e789 [PMC free article] [PubMed] [Google Scholar].
Chuang Y.-Y., Huang Y.-C., Lin T.-Y. Toxic Shock Syndrome in Children. Pediatric Drugs. 2005. 7(1). 11-25 [PubMed] [Google Scholar].
Royal College of Paediatrics and Child Health (RCPCH) Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. May 2020. https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf. July 30, 2020 [Google Scholar].
Centers for Disease Control and Prevention: Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). 14 May 2020. https://www.cdc.gov/mis-c/hcp/. July 30, 2020 [Google Scholar].
Istituito Superiore di Sanità. Indicazioni ad interim su malattia di Kawasaki e sindrome infiammatoria acuta multisistemica in età pediatrica e adolescienziale nell’attuale scenario emergenziale da infezione Sars-CoV-2. 2020, Rapporto ISS COVID-19 n. 29/2020 [Google Scholar].
Ramcharan T., Nolan O., Lai C.Y. et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatr. Cardiol. 2020 Jun. 1-11. doi: 10.1007/s00246-020-02391-2. Online ahead of print [PMC free article] [PubMed] [Google Scholar].
Belot A., Antona D., Renolleau S. et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro Surveill. 2020 Jun. 25(22). 2001010. doi: 10.2807/1560-7917.ES.2020.25.22.2001010 [PMC free article] [PubMed] [Google Scholar].
Pouletty M., Borocco C., Ouldali N. et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicenter cohort. Ann. Rheum. Dis. 2020 Aug. 79(8). 999-1006 [PMC free article] [PubMed] [Google Scholar].
Chiotos K., Bassiri H., Behrens E.M. et al. Multisystem Inflammatory Syndrome in Children During The Coronavirus 2019 Pandemic: A Case Series. J. Pediatric Infect. Dis. Soc. 2020 Jul 13. 9(3). 393-398 [PMC free article] [PubMed] [Google Scholar].
Henderson L.A., Canna S.W., Schulert G.S. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020 Jul. 72(7). 1059-1063 [PMC free article] [PubMed] [Google Scholar].
Molloy E.J., Bearer C.F. COVID-19 in children and altered inflammatory responses. Pediatr. Res. 2020. doi: 10.1038/s41390-020-0881-y. Рublished online April 3 [PubMed] [Google Scholar].
Roncati L., Ligabue G., Fabbiani L., Malagoli C. Type 3 hypersensitivity in COVID-19 vasculitis. Clin. Immunol. 2020. 217 [PMC free article] [PubMed] [Google Scholar].
Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. 395. 497-506. doi: 10.1016/S0140-6736(20)301835 [PMC free article] [PubMed] [Google Scholar].
Nakra N.A., Blumberg D.A., Herrera-Guerra A., Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed management. Children. 2020. 7. 69 [PMC free article] [PubMed] [Google Scholar].
The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N. Engl. J. Med. DOI: 10.1056/NEJMoa2021436 [PMC free article] [PubMed] [Google Scholar].
Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. 30. 269-271 [PMC free article] [PubMed] [Google Scholar].
Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L., Cheng Z., Lu Q. et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020. 395. 1569-1578 [PMC free article] [PubMed] [Google Scholar].
Feldstein L.R., Rose E.B., Horwitz S.M. et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N. Engl. J. Med. 2020 Jul 23. 383(4). 334-346 [PMC free article] [PubMed] [Google Scholar].
Lami F., Scalabrini I., Lucaccioni L., Iughetti L. The perfect storm: Current evidence on pediatric inﬂammatory multisystem disease during SARS-CoV-2 pandemic. Acta Biomed. 2020. 91(3). e2020034 [PMC free article] [PubMed] [Google Scholar].
Marchesi A., Tarissi de Jacobis I., Rigante D. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I — deﬁnition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital. J. Pediatr. 2018. 44. 102 [PMC free article] [PubMed] [Google Scholar].
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.